Our results may indicate the effectiveness of PD-1 and CTLA-4 as biomarkers for HCC and potential immunotherapy targets, enhancing our understanding of immune-related mechanisms underlying HCC and facilitating the development of personalized treatment strategies. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.